Yasunori Kogure

Senior Researcher

National Cancer Center Research Institute
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (30)

Year:

2026

Year:

2026

Year:

2026

Supplementary Figure S1. Analytical workflow for the C-CAT, GENIE, and TCGA cohorts. Supplementary Figure S2. Comparison of targeted gene panels. Supplementary Figure S3. Comparison of genetic alterations in C-CAT and GENIE cohorts. Supplementary Figure S4. Comparison of mutation frequency, type, and position in C-CAT and GENIE cohorts. Supplementary Figure S5. Co-occurring and mutually exclusive relationships across cohorts. Supplementary Figure S6. Co-occurring and mutually exclusive relationships across cancer types/subtypes. Supplementary Figure S7. Co-occurring and mutually exclusive relationships using a permutation approach. Supplementary Figure S8. Co-occurring and mutually exclusive relationships across driver mutations in epigenetic regulators. Supplementary Figure S9. Functional and prognostic relevance of driver mutations in epigenetic regulators.

Year:

2026

Background Plasma fibrinogen (FNG) is a prognostic marker in esophageal squamous cell carcinoma (ESCC). However, its predictive value for immune checkpoint inhibitor (ICI) efficacy and the underlying mechanisms remain unclear. This study aimed to evaluate the clinical significance of plasma FNG levels in ICI‐treated ESCC patients and investigate its association with tumor‐associated neutrophils (TANs) and genomic alterations. Methods A retrospective, multicenter analysis of 167 ESCC patients treated with ICIs was performed. TANs were quantified via immunohistochemistry using CD11b and CD66b staining, and PD‐L1 expression was assessed using the tumor proportion score (TPS). Whole‐exome and RNA sequencing were conducted to analyze genomic and transcriptomic profiles. Results Elevated plasma FNG levels correlated with lower ICI response rates and decreased survival. In first‐line treatment, chemo‐ICI therapy demonstrated superior efficacy compared to dual‐ICI therapy in high‐FNG patients, while the reverse trend was observed in low‐FNG patients. High‐FNG tumors showed increased TAN infiltration, independent of PD‐L1 expression. RNA sequencing revealed enrichment of neutrophil activation and extravasation pathways in high‐FNG tumors. Conclusions Elevated plasma FNG levels predict poor prognosis and reduced ICI efficacy in ESCC. They may be potential biomarkers for first‐line ICI‐based therapy and correlate with TAN infiltration. Further validation and mechanistic investigations are warranted.

Year:

2026

Using 48,627 samples from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), we present a pan-cancer landscape of driver alterations and their clinical actionability in Japanese patients. Comparison with White patients in Genomics Evidence Neoplasia Information Exchange (GENIE) demonstrates high TP53 mutation frequencies in Asian patients across multiple cancer types. Integration of C-CAT, GENIE, and The Cancer Genome Atlas data reveals many cooccurring and mutually exclusive relationships between driver mutations. At pathway level, mutations in epigenetic regulators frequently cooccur with PI3K pathway molecules. Furthermore, we found significant cooccurring mutations within the epigenetic pathway. Accumulation of mutations in epigenetic regulators causes increased proliferation-related transcriptomic signatures. Loss-of-function of many epigenetic drivers inhibits cell proliferation in their wild-type cell lines, but this effect is attenuated in those harboring mutations of not only the same but also different epigenetic drivers. Our analyses dissect various genetic properties and provide valuable resources for precision medicine in cancer. Significance: We present a genetic landscape of 26 principal cancer types/subtypes, including Asian-prevalent ones, in Japanese patients. Multicohort data integration unveils numerous cooccurring and exclusive relationships between driver mutations, identifying cooccurrence of multiple mutations in epigenetic regulators, which coordinately cause transcriptional and phenotypic changes. These findings provide insights into epigenetic regulator–driven oncogenesis. This article is featured in Selected Articles from This Issue, p. 695

Year:

2026

Year:

2025

Programmed death-ligand 1 (PD-L1/CD274) structural variation (SV) disrupting the 3′-untranslated region has been highlighted as being associated with PD-L1 overexpression. In the present study, we evaluated lymphoma tissue samples to investigate the applicability of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for detecting the PD-L1 SV involving the 3′-untranslated region. In total, 1052 lymphoma samples were screened using IHC, and 99 IHC screening-positive samples were evaluated with FISH (non-Hodgkin lymphoma [NHL, n=58] and Hodgkin lymphoma [HL, n=41]). Of these, 92 samples showed strong PD-L1 expression with 2 PD-L1 antibodies (E1J2J and SP142) (concordant PD-L1 IHC), whereas 7 samples showed strong PD-L1 expression only with E1J2J (discordant PD-L1 IHC). Abnormal FISH findings for PD-L1 were detected in all evaluated samples (51 NHLs and 41 HLs). A structural abnormality pattern was observed in 17 of the 51 evaluated NHL samples (33%). In contrast, all 41 HL samples showed a copy number abnormality pattern, with 1 exhibiting a structural abnormality pattern. Target-capture sequencing of the PD-L1 gene was performed on 73 of the 99 IHC screening-positive samples, comprising 41 NHLs and 32 HLs. PD-L1 SVs were detected in 16 (39%) of the 41 NHL samples and in only one of the 32 HL samples (3%). Samples exhibiting discordant PD-L1 IHC and/or FISH structural abnormality patterns were shown to harbor PD-L1 SV by target-capture sequencing, with positive and negative predictive values of 94% and 96%, respectively. Our approach is an alternative to target-capture sequencing for evaluating PD-L1 gene abnormalities.

Year:

2025

Year:

2025

Phospholipase C gamma 1 ( PLCG1 ) has been identified as the most frequently mutated gene in adult T-cell leukemia/lymphoma, suggesting a critical function of PLCG1 in driving T cell activation. However, it remains unclear how these mutations regulate T cell physiology and pathology. Here, we investigate three common leukemia/lymphoma-associated mutations (R48W, S345F, and D1165H). We discover that these mutations induce hyperactive T cell signaling and cause pro-survival phenotypes. PLCG1 mutants enhance LAT condensation, calcium influx, and ERK activation. They also promote T cell proliferation, upregulate cell adhesion molecules, induce cell aggregation, and confer resistance to Vorinostat, an FDA-approved drug for cutaneous T-cell lymphoma. The resistance depends on ERK signaling and can be reversed with an ERK inhibitor. Interestingly, PLCG1 mutants also induce bystander drug resistance in nearby cells expressing wild-type PLCG1. Mechanistically, alpha smooth muscle actin, which is specifically induced by PLCG1 mutants, directly binds PLCG1 to promote its activation. These results demonstrate that hyperactive PLCG1 promotes T cell survival and drug resistance by inducing non-canonical signaling.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (41)

Katherine Hoadley

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Claire Palles

Associate Professor

University of Birmingham

UNITED KINGDOM
View details

Junji Koya

Senior Staff Scientist

National Cancer Center Research Institute

JAPAN
View details

Ines Gockel

University Hospital Leipzig

GERMANY
View details

Johannes Schumacher

Philipps-Universität Marburg

GERMANY
View details

Masaki Iino

Professor

University of Yamanashi Hospital

JAPAN
View details

Axel Hillmer

Assoc. Prof

University Hospital Bonn

GERMANY
View details

Puya Gharahkhani

Team Head, Associate Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Takahiro Maeda

Professor

Kyushu University Graduate School of Medical Sciences

JAPAN
View details

Felipe Suarez

Professor

Université Paris-Saclay

FRANCE
View details

Akshay Joshi

University College London

UNITED KINGDOM
View details

Vahid Asnafi

-

FRANCE
View details

Seishi Ogawa

Kyoto University

JAPAN
View details

Koichi Ohshima

Professor

Kurume University

JAPAN
View details

Takanori Kanai

-

JAPAN
View details

Ian Tomlinson

University of Edinburgh

UNITED KINGDOM
View details

Keisuke Kataoka

Chief

National Cancer Center Research Institute

JAPAN
View details

Carlo Maj

Head of Bioinformatics | Research Group Leader – Genetic Epidemiology

University of Marburg

GERMANY
View details

Jean‐Marie Michot

-

FRANCE
View details

Sumito Shingaki

New York University

UNITED STATES
View details

Quinn Ostrom

Assistant Professor

Duke University School of Medicine

UNITED STATES
View details

David Whiteman

Deputy Director

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Beatrice Melin

Professor

Umea University

SWEDEN
View details

Hiroaki Miyoshi

Professor

Kurume University

JAPAN
View details

Isabelle André

Université Paris Descartes

FRANCE
View details

Stuart MacGregor

Professor

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Dominik Heider

Diretor

University of Münster

GERMANY
View details

Gandhi Damaj

Professor, M.D. Head of departement

University Hospital

FRANCE
View details

David Wedge

The University of Manchester

UNITED KINGDOM
View details

Niels Olsen Saraiva Camara

Professor Titular

University of Sao Paulo

BRAZIL
View details

Helder Nakaya

Associate Professor

University of Sao Paulo

BRAZIL
View details

Melissa Bondy

Professor/Department Chair

Stanford University

UNITED STATES
View details

Yukinori Okada

University of Tokyo

JAPAN
View details

Janusz Jankowski

Professor

University College London

UNITED KINGDOM
View details

Kazuki Sato

Assistant Professor

University of Tsukuba

JAPAN
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Laurence de Leval

Director of the Institute of Pathology / Professor of Pathology

Lausanne University Hospital

SWITZERLAND
View details

Sachiko Tsukita

-

JAPAN
View details

Ayumi Fujimoto

Shimane University Hospital

JAPAN
View details

Koji Izutsu

Chief, Department of Hematology

National Cancer Center Hospital

JAPAN
View details

Yuki Saito

National Cancer Center Research Institute

JAPAN
View details